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Abstract
Translocator protein (TSPO) takes part in mitochondrial adenine triphosphate (ATP) pro-
duction and transport. Mitochondrial TSPO is a part of the apoptotic and cell necrotic
mechanism. Ligands to TSPO, endogenous and synthetic, have different effects on metabo-
lism and protein expression in human well-differentiated metabolically active cells. In
general, most of the TSPO ligands affect the cellular function or metabolism in the same
general direction, but different specific TSPO ligands have their own unique effects in
human cells. Regulation of gene expression via the actions of TSPO ligands on the mito-
chondrial TSPO may form an essential mechanism for the regulation of cellular functions,
especially during acute organ injury, such as acute brain damage. The exact mode of action
of the specific TSPO ligands is not clear enough and should be further investigated. TSPO is
a potential target for therapeutic efforts to mitigate secondary tissue injury caused by
programmed cell death.
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1. The structure, abundance and function of TSPO
The 18 kDa translocator protein (TSPO), previously known as a peripheral benzodiazepine
receptor (PBR) [1], is a highly conserved protein with various life essential functions in eukary-
otic and prokaryotic species [2]. The TSPO gene in humans is situated on the chromosome
22q13.3 [3]. The amino acid sequence of TSPO of human origin (169 amino acids): 1
mappwvpamg ftlapslgcf vgsrfvhgeg lrwyaglqkp swhpphwvlg pvwgtlysam 61 gygsylvwke
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lggftekavv plglytgqla lnwawppiff garqmgwalv dlllvsgaaa 121 attvawyqvs plaarllypy lawlaftttl
nycvwrdnhg wrggrrlpe [4].
TSPO takes part in mitochondrial ATP production and transport, and is located on cytoplasmic
and nuclear membranes and on the outer membrane of mitochondria. TSPO is abundant in
metabolically active cells in different organs, such as brain, kidney, and so forth. [2]. TSPO has
been also found in other organs and generally is abundant in steroid-secreting tissues. Recently,
it has been detected in high abundance in osteoblasts [5]. TSPO interacts with ligands to
modulate various molecular cellular activities [5–9] by affecting cell death. TSPO is thought to
be involved in mitochondrial cholesterol transport and related to cell death pathways (apoptosis
and necrosis) as a functional part of the mitochondrial permeability transition pore (MPTP),
along with additional related receptors and protein structures, for example, voltage-dependent
anion channel (VDAC) and the adenine nucleotide translocase (ANT) [1, 2]. The existence of
functional interconnection between TSPO and MPTP has been challenged recently in studies
showing that the MPTP can induce apoptosis and cholesterol transport without the involvement
of TSPO [10]. Thus, the exact mechanism of the TSPO involvement in cell death has not been
determined yet, but its functional role in this process is strongly supported [1, 2, 6–8].
2. TSPO ligands
Ligands, either endogenous or synthetic, to TSPO, such as protoporphyrin IX (PPIX), PK
11195, Ro5–4864, FGIN-1-27, induce different effects on metabolism and protein expression in
human well-differentiated metabolically active cells. For example, Ro5–4864, FGIN-1-27 and
PPIX cause similar effects, for example, reducing cellular [18F]-fluorodeoxyglucose ([18F]-FDG)
incorporation and parallel decrease in ATP generation [6–8]. The cellular effects of PK 11195
show protective attempts for cellular “detoxification” by increasing the cellular mitochondrial
mass (Figure 1) [5].
In general, most of the TSPO ligands affect the cellular function or metabolism in the same
general direction, but different specific TSPO ligands have their own unique effects in human
cells. Regulation of gene expression via the actions of TSPO ligands on the mitochondrial
TSPO may form an essential mechanism for the regulation of cellular functions.
The exact mode of action of the specific TSPO ligands is not clear enough and should be further
investigated. Due to the evidence of the nonuniform response of cells to the different specific
ligands, an attempt to elucidate the role of the TSPO in cellular metabolism and modulation of
cell phenotype should be promoted.
3. TSPO role in organ pathology and injury
Changes in TSPO expression have been linked to several pathological conditions, including
cancer, endocrine diseases, and neurological diseases [2]. For example, in the normal brain,
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overall TSPO expression is low, and TSPO is mainly found in glia and at very low levels in
neurons [9]. But in the abnormal brain, TSPO is mainly expressed in glia, some hypertrophic
astrocytes, infiltrating macrophages, and at low levels in neurons.
TSPO expression is upregulated in the injured brain and topographically localized in the
inflamed areas. Additionally, in various neuropathologies, that is, gliomas, ischemia, viral
encephalitis, neurodegenerative disorders (Parkinson’s disease, Huntington’s disease,
Alzheimer’s disease, and amyotrophic lateral sclerosis), local high expression of TSPO is
evident [9–11, 12].
Mitochondria are the key regulators of cell survival and death. Mitochondria interact with
numerous specific proteins, which are involved in genetic forms of neurodegenerative diseases
[5, 9, 11]. When TSPO is a mitochondrial protein, it plays an important role in various cellular
pathways related to brain damage and neurodegenerative disease [12].
The potential intracellular mechanisms related to TSPO include Ca++ release, ATP production,
reactive oxygen species (ROS) generation, and cytochrome C release from the mitochondria in
relation to programmed cell death [7, 13, 14].
Figure 1. A: Microscopic image of cells stained by Mitotracker green stain (MTG). Strings of green stained mitochondria
are apparent. Confocal microscopy, scale – 20 μ. B: Flow cytometry of cells stained by MTG. The histogram of the
mitochondrial mass is shifted showing when exposed to PK 11195 (105 M) indicating on increase in the mitochondrial
mass in comparison with the unexposed control.
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4. TSPO role in cell death: the case of neural injury
Regulation of programmed cell death is not sufficient to establish tissue repair. In brain
pathologies, when the TSPO is upregulated, there is a typical association with microglial
activation and inflammation. High level of TSPO expression in glia, as well as the increased
proliferation of microglia in gliosis, suggests that TSPO could serve as an index of the state and
progression of traumatic brain injury (TBI) [3]. These studies suggest that TSPO expression
measurement can be used as a biomarker of active brain disease. The precise etiology of
differences in TSPO expression and its relation to injury to neural tissue, while TBI or in
neurodegenerative conditions, have not been resolved yet [14].
It is possible that high TSPO local brain tissue concentration might be an etiologic factor in
progressive tissue damage in TBI. This theory is based on the revealed TSPO role in the
cholesterol transport via inner mitochondrial membrane that accelerates cell proliferation
during reactive gliosis, which is an essential part in the pathogenesis following TBI [10].
Secondary injury has the most important effect in brain damage related to TBI. This process is
caused predominantly by mitochondrial shutdown. Mitochondrial dysfunction progresses to
apoptosis by the increase in oxidative stress due to depleted ATP synthesis. The final result is a
local to the injured site brain tissue damage that is clinically expressed by a spectrum of
cognitive or motoric impairments. Therefore, it might be logical to suggest that therapeutic
efforts in TBI should address cellular pathways connected to TSPO. But there is no current
therapeutic evidence that can support this hypothesis, and therefore this is a highly appealing
area for further research. There is an ongoing research on novel methods to prevent, diagnose,
and treat TBI focusing on maintaining mitochondrial function [15, 16].
TBI is still the leading cause of disability in young adults worldwide. Its major mechanisms are
diffuse axonal injury, cerebral contusion, ischemic neurological damage, and intracranial hema-
tomas. All these pathologies are associated to some extent with mitochondrial dysfunction [15].
Significant necrosis of the brain cortical tissue occurs rapidly upon experimental TBI. Exacer-
bation of the primary lesion occurs during the hours after the brain injury and leads conse-
quently to significant neurological dysfunction. Cyclosporine A (CsA, an immunosuppressant)
has shown a neuroprotective role in TBI. CsA inhibits the opening of the MPTP, which in turn
maintains the mitochondrial membrane potential, and calcium homeostasis of mitochondria.
These results demonstrate that MPTP modulation and mitochondrial homeostasis mainte-
nance are related to the neuroprotective role of CsA. The CsA neuroprotective effect following
brain injury indicated that pharmacological therapies can be designed to greatly affect the
mitochondria and neurological outcome following a brain injury [15]. Since TSPO has been
suggested to be functionally related to the MPTP, it might be involved in these cellular
pathways and might be targeted in the future research of TBI treatment.
One of the cellular pathways following TBI at the cellular level is related to energetic shut-
down, with subsequential interference with Ca2+ homeostasis. This process starts following
initial brain injury by an “ischemia-like” pattern, after direct impact to the brain tissue. Addi-
tionally, this process causes impairment in the cerebral blood flow, with further local ischemic
process. As the result of this initial impact, the cellular ATP synthesis decreases, and
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mitochondrial membrane potential collapses. As a result, the nerve terminal membrane is
depolarized, glutamate and aspartate (excitatory neurotransmitters) are released and voltage-
dependent Ca2+ and Na+ channels are activated. By the self-accelerating process, additional
Ca2+ is recruited causing its pathologically increased concentration. The Ca2+ overload causes
increased catabolic effect due to enhanced release of free radicals, with eventual cell death via
cellular membrane damage [16].
ATP production via oxidative phosphorylation is the primary function of mitochondria, and
Ca2+ is the characteristic stimulatory signal for the activation of numerous mitochondrial
enzymes [16]. Mitochondria play a pivotal role in cell survival. Mitochondrial dysfunction is
an early event in the CNS injury that progresses to cell necrosis.
Thus, the cell death, neural and glial, following TBI is the pathophysiological cause for overall
brain damage. Cell death occurs by apoptosis, autophagy, and necrosis [17, 18]. A programmed
cell necrosis (necroptosis) has a distinct and characteristic morphology due to autophagy [19].
Mitochondria are the source to cell death propagation, in addition to the extrinsic pathway and
caspase-12-mediated endoplasmic reticulum (ER) apoptotic pathway. The extrinsic pathway is
amplificated by mitochondria and causes apoptosis. The BH3-only protein Bid links the extrinsic
and mitochondrial apoptosis. The mitochondrial apoptosis can be caspase-dependent or inde-
pendent. If caspase-dependent, it involves cytochrome C, otherwise apoptosis inducing factor
(AIF) governs the caspase-independent pathway.
Therefore, it may be deduced, according to the abovementioned studies, that mitochondrial
membrane, Ca2+ and reactive oxygen species (ROS) are shown to mediate synergistically the
process of cell damage induced by TBI. Mitochondrial outer membrane permeabilization
(MOMP) and mitochondrial permeability transition (MPT), which are part of apoptotic path-
way, are the suggested mechanisms of the pores’ formation in the mitochondrial membranes.
An additional important factor, the Bcl-2 family, is regulatory in apoptosis and cell necrosis as
well. There are also numerous other proapoptotic factors that might be interconnected with the
mentioned pathways, but their role is not clear. These factors coordinate the apoptotic activity
and related to mitochondria, ER, and lysosome.
The regulation of Ca2+ flux between mitochondria and ER is a control point during apoptosis,
along with mitochondria-associated membranes. It is important to mention that the cathepsin
proteases that are released from lysosome enhance the mitochondria-mediated cell death.
These cellular events are related to secondary brain damage and other pathological processes
involving programmed cell death.
Additional cellular pathways, not directly related to mitochondria, such as neuron cells death
by excitotoxicity, due to elevated levels of synaptic neurotransmitters, also occur during TBI.
Excitotoxicity is mediated by glutamate and involves several synaptic receptors, for example,
AMPA, NMDA, voltage-dependent Ca2+ channels (VDCC) and metabotropic glutamate
(mGlu) receptors [13, 20, 21]. The Na+- and Cl-dependent influx is associated with immediate
cell swelling [22–25]. Extra-synaptic NMDA receptor activation can activate a cAMP response
element binding (CREB) protein shut-off which, in turn, causes loss of ΔΨm and apoptosis [26].
Stress-activated protein kinases (SAPKs) are another class of signaling molecules that are part of
NMDA receptor-dependent cell death [27].
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Eventually, the mitochondrial membrane is one of the last barriers to cell death. Different
receptors related to the mitochondrial membrane, including TSPO, have a crucial role in
protection from or propagation to cell death. In the case of the secondary damage following
TBI, the possibility of therapeutic targeting of this receptor has been raised [28].
The preservation of energy supply alone is not enough for mitochondria protection. The
ongoing research on TSPO might also lead to the finding of protective pathways that will
avoid the cell death cascades during the brain or other tissue injury. In the series of four papers,
it was found that from all studied, only one type of synthetic TSPO ligand, PK 11195 (105 M),
evolves a protective cellular response by elevating the cellular mitochondrial mass [6]. PK
11195 is unsuitable for clinical use because of its overall toxic effects in vivo, but it is clear that
its interaction with TSPO evolves a protective anti-necrotic effect in cells. Therefore, TSPO is a
good candidate for future research of mitigation of secondary tissue damage which is cur-
rently irreversible.
In conclusion, mitochondria play a pivotal role in the secondary cellular insult such as in the TBI
and other types of tissue necrotic damage. The mitochondrial malfunction that occurs during
such pathological effects results in cellular energy loss, with the activation of cell death path-
ways, which involve the interrelated actions of excitotoxicity, ROS, caspases, the Bcl-2 family and
apoptosis inducing factor (AIF). In this process, the role of TSPO is still elusive but with a strong
indication of a possible regulatory involvement [5]. With the clarification of the function and
structure of TSPO on mitochondria, mitochondrial-targeted multipotential therapeutic strategies
via TSPO might provide new hope for the treatment of cellular death, such as in TBI or in other
acute injury states in other organs, with high energy demanding cellular content.
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